Ice Pharma Expands Beyond APIs to Create New Bile Acid Markets
Ice Pharma recently announced a strategic expansion beyond its core active pharmaceutical ingredient (API) business, positioning the company to compete in higher-value finished dosage, nutraceutical, and specialty excipient markets.
Long recognized as a leader in ursodeoxycholic acid (UDCA) APIs, Ice Pharma is leveraging its vertically integrated bile acid platform to move closer to the end market and diversify revenue streams across pharmaceutical and health-driven sectors.
“Ice Pharma is evolving beyond the traditional API supplier model by exploring and developing new applications of bile acids, with the goal of opening new market opportunities,” said Agostino Barazza, Chief Executive Officer of Ice Pharma. “Our expansion into UDCA finished dosage forms, nutraceutical platforms, and bile acid-based excipients reflects a deliberate strategy to increase value creation and strengthen long-term growth.”
The company’s growth strategy is centred on three strategic pillars:
- UDCA Finished Dosage Forms (FDF) — Delivering fully developed UDCA products to complement its established API leadership, enabling end-to-end value creation.
- Nutra Platform — Advancing bile acid-based nutraceutical solutions targeting gut health and metabolic balance, addressing rising demand in preventive healthcare.
- Non-API Applications & Excipients — Expanding bile acid derivatives into functional excipients and specialty products that enhance formulation performance across pharmaceutical and related markets.
“Bile acids are an underutilized but highly versatile molecular class,” said Roger Viney, Chief Commercial Officer of Ice Pharma. “Our strategy is to leverage our chemistry, regulatory expertise, and manufacturing infrastructure to provide integrated solutions — not just ingredients — to pharmaceutical and healthcare partners.”
This strategic shift will also drive a refreshed global marketing campaign, aligning Ice Pharma’s messaging with its broadened portfolio and solution-oriented value proposition.
